Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 27;14(10):2057.
doi: 10.3390/pharmaceutics14102057.

Platinum(IV) Complexes of the 1,3,5-Triamino Analogue of the Biomolecule Cis-Inositol Designed as Innovative Antineoplastic Drug Candidates

Affiliations

Platinum(IV) Complexes of the 1,3,5-Triamino Analogue of the Biomolecule Cis-Inositol Designed as Innovative Antineoplastic Drug Candidates

Vyara Velcheva et al. Pharmaceutics. .

Abstract

Metal complexes occupy a special place in the field of treatment and diagnostics. Their main advantages stem from the possibility of fine-tuning their thermodynamic properties and kinetic behavior in the biological milieu by applying different approaches such as properly constructed inner coordination sphere, appropriate choice of ligands, metal oxidation state, redox potential, etc., which are specific to these compounds. Here we discuss the design and synthesis of two octahedral cationic Pt(IV) complexes of the tridentate ligand all-cis-2,4,6-triaminocyclohexane-1,3,5-triol (taci) with composition, fac-[Pt(taci)I3]+, 1 and bis-[Pt(taci)2]4+, 2 as well as the potential for their application as antineoplastic agents. The complexes have been isolated in a solid state as: fac-[Pt(taci)I3]I·3H2O (1A), fac-[Pt(taci)I3]I (1B), fac-[Pt(taci)I3]I·2DMF (1C), bis-[Pt(taci)2](CO3)2·6H2O (2A) by changing the acidity of the reaction systems, the molar ratios of the reagents and the counterions, and by re-crystallization. The ligand taci is coordinated through the NH2-groups, each molecule occupying three coordination places in the inner coordination sphere of Pt(IV). Monitoring of the hydrolysis processes of 1A and 2A at different acidity showed that while 2A remained stable over the study period, the I--ions in 1A were successively substituted, with the main product under physiologically mimetic conditions being fac,cis-[Pt(taci)I(OH)2]+ (h2). The antiproliferative tests involved eight cancer cell models, among which chemosensitive (derived from leukemias and solid tumors) and chemoresistant human Acute myeloid leukemia lines (HL-60/Dox, HL-60/CDDP), as well as the non-malignant kidney' cells HEK-293T showed that the complexes 1A and 2A are characterized by a fundamentally different profile of chemosensitivity and spectrum of cytotoxic activity compared to cisplatin. The new Pt(IV) complexes were shown to be more effective in selectively inhibiting the proliferation of human malignant cells compared to cisplatin. Remarkable activity was recorded for 1A, which showed an effect (IC50 = 8.9 ± 2.4) at more than 16-fold lower concentration than cisplatin (IC50 = 144.4 ± 9.8) against the resistant cell line HL-60/CDDP. In parallel, 1A exhibited virtually the same cytotoxic effect against the parental HL-60 cells (IC50 = 9.0 ± 1.2), where cisplatin displays comparable chemosensitivity (IC50 = 8.3 ± 0.8). The determined resistance indices (RI~1) show unequivocally that the resistant lines are sensitive to both compounds tested; therefore, they are capable of overcoming the mechanisms of cisplatin resistance. The structural features of these compounds and their promising pharmacological properties justify their inclusion in the group of "non-classical metal-based antitumor compounds" and are a prerequisite for the admission of alternative mechanisms of action.

Keywords: Pt(IV) complexes; biological activity; cisplatin resistance; novel metal-based drugs; structure-activity studies; synthesis and characterization.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Scheme 1
Scheme 1
Molecular structure of platinum antitumor compounds: (a) platinum(II) complexes; (b) platinum(IV) complexes; (c) platinum(IV) complexes investigated in this study.
Scheme 2
Scheme 2
Synthesis of 1 and isolation as red crystals, 1A.
Scheme 3
Scheme 3
Synthesis of 2 and isolation as yellow crystals, 2A.
Figure 1
Figure 1
The conformation and atom numbering scheme in the complex cations: (a) [PtI3(taci)]+, 1; (b) [Pt(taci)2]4+, 2. The thermal displacement ellipsoids at a 30% probability level are used for non-H-atoms. H-atoms are omitted for clarity.
Figure 2
Figure 2
H-bond networks in the crystal structures of 1A (a) and 2A (b). The solvent and carbonate atoms are presented as balls for clarity.
Figure 3
Figure 3
IR spectra (CsI disks): 1-taciplatin (red), 1A; 2-ditaciplatin (black), 2A; 3-taci·2H2O (blue).
Figure 4
Figure 4
1H NMR spectra of taci, 1 and 2 in D2O and corresponding HR-ESI(+)−MS signals (H2O).
Scheme 4
Scheme 4
Hydrolytic species of complex 1.
Figure 5
Figure 5
1H-1H COSY NMR spectrum of 1, immediately after adding NaOD (pD = 7.8).
Figure 6
Figure 6
EIS(+)-MS spectrum of 1A (1 mg/L in H2O at pH = 7.4 (by adding NaOH)).
Figure 7
Figure 7
Cell growth inhibitory effects of complex 1A, complex 2A vs. cisplatin against a panel of human tumor cell lines after 72 h continuous exposure (MTT-dye reduction). Each data point represents the arithmetic mean ± sd of 8 separate experiments.
Figure 8
Figure 8
Comparative representation of “mean graph” diagrams generated for the novel compounds and Cis-DDP. Each “mean graph” represents a pattern created by plotting positive and negative values (deltas) generated from the set of IC50 values. The positive and negative values are plotted along a vertical line representing the mean response of all the cell lines in the panel to the tested compound. The negative values project to the left of the neutral vertical line and denote cellular sensitivities to the tested agent that exceed its mean activity. The positive deltas project to the right and represent cell line sensitivities to the test agent that are less than the average inhibitory activity value.
Figure 9
Figure 9
Cell growth inhibitory effects of 1A, 2A vs. cisplatin against human embryonic kidney cell line HEK-293T after 72 h continuous exposure (MTT-dye reduction). Each data point represents the arithmetic mean ± SD of 8 separate experiments.
Figure 10
Figure 10
Index of selectivity of 1A, 2A, and cisplatin presented in arbitrary units against the IC50 values determined in non-malignant cell line HEK-293T.

References

    1. Mjos K.D., Orvig C. Metallodrugs in Medicinal Inorganic Chemistry. Chem. Rev. 2014;114:4540–4563. doi: 10.1021/cr400460s. - DOI - PubMed
    1. Rosenberg B., Van Camp L., Krigas T. Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode. Nature. 1965;205:698–699. doi: 10.1038/205698a0. - DOI - PubMed
    1. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. 2007;7:573–584. doi: 10.1038/nrc2167. - DOI - PubMed
    1. Rottenberg S., Disler C., Perego P. The rediscovery of platinum-based cancer therapy. Nat. Cancer. 2021;21:37–50. doi: 10.1038/s41568-020-00308-y. - DOI - PubMed
    1. Hartmann J.T., Lipp H.-P. Toxicity of platinum compounds. Expert Opin. Pharmacother. 2003;4:889–901. doi: 10.1517/14656566.4.6.889. - DOI - PubMed

LinkOut - more resources